{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:07:13Z","timestamp":1794863233459,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The relationship between nanoliposomal irinotecan\/fluorouracil\/leucovorin (NFF) treatment outcomes and neutropenia in patients with pancreatic cancer has not been thoroughly examined. Thus, we conducted a retrospective analysis of data from patients with pancreatic cancer who were treated with NFF to investigate this relationship. Neutropenia was assessed according to the Common Terminology Criteria for Adverse Events across three cutoffs: A (grade 0 versus grade 1\u20134), B (grades 0\u20131 versus 2\u20134), and C (grades 0\u20132 versus 3\u20134). The primary endpoint was overall survival (OS), and the secondary endpoints were overall response rate, progression-free survival (PFS), and relative dose intensity. Of the 161 patients, 93, 8, 22, 30, and 8 patients had neutropenia of grades 0, 1, 2, 3, and 4, respectively. The overall response rates differed significantly at cutoff C (<jats:italic>p<\/jats:italic>\u2009=\u20090.02), with the odds ratio for cutoff C being the highest, followed by cutoffs B and A. Significant differences in OS were observed at cutoffs A (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.44\u20130.94; <jats:italic>p<\/jats:italic>\u2009=\u20090.02) and B (HR, 0.63; 95% CI, 0.43\u20130.92, <jats:italic>p<\/jats:italic>\u2009=\u20090.02). Similarly, PFS showed significant differences at cutoffs A and B (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). NFF-induced neutropenia can be a useful prognostic factor for patients with pancreatic cancer.<\/jats:p>","DOI":"10.1038\/s41598-025-88005-4","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T19:45:48Z","timestamp":1738007148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Relationship between neutropenia caused by nanoliposomal irinotecan\/fluorouracil\/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)"],"prefix":"10.1038","volume":"15","author":[{"given":"Tomonori","family":"Araki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futa","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Kubotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hozumi","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Otsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanobu","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Kawahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Tsuneyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Sakae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9317-8216","authenticated-orcid":false,"given":"Tsuyoshi","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Mitsugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"88005_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"Cancer J. Clin."},{"key":"88005_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N Engl. J. Med."},{"key":"88005_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N Engl. J. Med."},{"key":"88005_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam, A. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387, 545\u2013557 (2016).","journal-title":"Lancet"},{"key":"88005_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","volume":"108","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam, A. et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur. J. Cancer. 108, 78\u201387 (2019).","journal-title":"Eur. J. Cancer"},{"key":"88005_CR6","doi-asserted-by":"publisher","first-page":"9396","DOI":"10.1002\/cam4.3558","volume":"9","author":"M Ueno","year":"2020","unstructured":"Ueno, M. et al. nal-IRI\u2009+\u20095-FU\/LV versus 5-FU\/LV in post-gemcitabine metastatic pancreatic cancer: randomized phase 2 trial in Japanese patients. Cancer Med. 9, 9396\u20139408 (2020).","journal-title":"Cancer Med."},{"key":"88005_CR7","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1111\/cas.15377","volume":"113","author":"G Milano","year":"2022","unstructured":"Milano, G., Innocenti, F. & Minami, H. Liposomal irinotecan (Onivyde): exemplifying the benefits of nanotherapeutic drugs. Cancer Sci. 113, 2224\u20132231 (2022).","journal-title":"Cancer Sci."},{"key":"88005_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12885-023-10542-w","volume":"23","author":"T Kawakami","year":"2023","unstructured":"Kawakami, T. et al. Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil\/leucovorin. BMC Cancer. 23, 68 (2023).","journal-title":"BMC Cancer"},{"key":"88005_CR9","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1158\/1078-0432.CCR-20-0395","volume":"26","author":"V Merz","year":"2020","unstructured":"Merz, V. et al. Plasma IL8 is a biomarker for TAK1 activation and predicts resistance to Nanoliposomal Irinotecan in patients with gemcitabine-refractory pancreatic Cancer. Clin. Cancer Res. 26, 4661\u20134669 (2020).","journal-title":"Clin. Cancer Res."},{"key":"88005_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cancers14010217","volume":"14","author":"N Sturm","year":"2022","unstructured":"Sturm, N., Ettrich, T. J. & Perkhofer, L. The impact of biomarkers in pancreatic ductal adenocarcinoma on diagnosis, Surveillance and Therapy. Cancers (Basel). 14, 217 (2022).","journal-title":"Cancers (Basel)"},{"key":"88005_CR11","doi-asserted-by":"publisher","first-page":"null","DOI":"10.3390\/cancers15041008","volume":"15","author":"Y-Y Su","year":"2023","unstructured":"Su, Y-Y. et al. Real-World Data Validation of NAPOLI-1 Nomogram for the prediction of overall survival in metastatic pancreatic Cancer. Cancers 15, null (2023).","journal-title":"Cancers"},{"key":"88005_CR12","doi-asserted-by":"publisher","first-page":"14337","DOI":"10.1002\/cam4.6111","volume":"12","author":"L Procaccio","year":"2023","unstructured":"Procaccio, L. et al. The role of nanoliposomal irinotecan plus fluorouracil\/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Cancer Med. 12, 14337\u201314345 (2023).","journal-title":"Cancer Med."},{"key":"88005_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.clcc.2016.07.005","volume":"16","author":"S Hamauchi","year":"2017","unstructured":"Hamauchi, S. et al. Neutropenia as a predictive factor in metastatic colorectal Cancer treated with TAS-102. Clin. Colorectal Cancer. 16, 51\u201357 (2017).","journal-title":"Clin. Colorectal Cancer"},{"key":"88005_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/sj.bjc.6605348","volume":"101","author":"Y Kishida","year":"2009","unstructured":"Kishida, Y. et al. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan multinational Trial Organization LC00-03. Br. J. Cancer. 101, 1537\u20131542 (2009).","journal-title":"Br. J. Cancer"},{"key":"88005_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40265-018-0909-3","volume":"78","author":"PM Kasi","year":"2018","unstructured":"Kasi, P. M. & Grothey, A. Chemotherapy-Induced Neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients. Drugs 78, 737\u2013745 (2018).","journal-title":"Drugs"},{"key":"88005_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1186\/s12885-021-08323-4","volume":"21","author":"P Gargiulo","year":"2021","unstructured":"Gargiulo, P. et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. BMC Cancer. 21, 549 (2021).","journal-title":"BMC Cancer"},{"key":"88005_CR17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(05)70255-2","volume":"6","author":"M Di Maio","year":"2005","unstructured":"Di Maio, M. et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 6, 669\u2013677 (2005).","journal-title":"Lancet Oncol."},{"key":"88005_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s40265-020-01336-6","volume":"80","author":"J Frampton","year":"2020","unstructured":"Frampton, J. Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma. Drugs 80, 1007\u20131018 (2020).","journal-title":"Drugs"},{"key":"88005_CR19","doi-asserted-by":"crossref","unstructured":"Brookmeyer, R. & Crowley, J. A confidence interval for the median survival time. Biometrics 29\u201341 (1982).","DOI":"10.2307\/2530286"},{"key":"88005_CR20","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/sj.bjc.6600139","volume":"86","author":"H Gurney","year":"2002","unstructured":"Gurney, H. How to calculate the dose of chemotherapy. Br. J. Cancer. 86, 1297\u20131302 (2002).","journal-title":"Br. J. Cancer"},{"key":"88005_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/SPC.0b013e32832ea6ae","volume":"3","author":"DC Dale","year":"2009","unstructured":"Dale, D. C. Advances in the treatment of Neutropenia. Curr. Opin. Support Palliat. Care. 3, 207\u2013212 (2009).","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"88005_CR22","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3390\/jcm12041596","volume":"12","author":"K Harada","year":"2023","unstructured":"Harada, K. et al. Correlation of UGT1A1 gene polymorphisms or prior Irinotecan Treatment and Treatment outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil\/Leucovorin for pancreatic ductal adenocarcinoma: a Multicenter, Retrospective Cohort Study (HGCSG2101). J. Clin. Med. 12, 1596 (2023).","journal-title":"J. Clin. Med."},{"key":"88005_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/jjco\/hyac177","volume":"53","author":"J Furuse","year":"2023","unstructured":"Furuse, J. et al. Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial. Jpn .J. Clin. Oncol. 53, 130\u2013137 (2023).","journal-title":"Jpn J. Clin. Oncol."},{"key":"88005_CR24","unstructured":"Japanese, G-C-S-F. guidelines. (2022). http:\/\/www.jsco-cpg.jp\/g-csf\/"},{"key":"88005_CR25","doi-asserted-by":"publisher","first-page":"595835","DOI":"10.3389\/fimmu.2020.595835","volume":"11","author":"PC Hart","year":"2020","unstructured":"Hart, P. C., Rajab, I. M., Alebraheem, M. & Potempa, L. A. C-Reactive protein and cancer-diagnostic and therapeutic insights. Front. Immunol. 11, 595835 (2020).","journal-title":"Front. Immunol."},{"key":"88005_CR26","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s10552-014-0445-8","volume":"25","author":"B Zhou","year":"2014","unstructured":"Zhou, B. et al. C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis. Cancer Causes Control. 25, 1397\u20131405 (2014).","journal-title":"Cancer Causes Control"},{"key":"88005_CR27","doi-asserted-by":"publisher","first-page":"744129","DOI":"10.3389\/fimmu.2021.744129","volume":"12","author":"LA Potempa","year":"2021","unstructured":"Potempa, L. A., Rajab, I. M., Olson, M. E. & Hart, P. C. C-Reactive protein and Cancer: interpreting the differential bioactivities of its pentameric and monomeric, modified isoforms. Front. Immunol. 12, 744129 (2021).","journal-title":"Front. Immunol."},{"key":"88005_CR28","doi-asserted-by":"publisher","first-page":"8815","DOI":"10.1038\/s41598-023-34962-7","volume":"13","author":"T Shirakawa","year":"2023","unstructured":"Shirakawa, T. et al. C-reactive protein\/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel. Sci. Rep. 13, 8815 (2023).","journal-title":"Sci. Rep."},{"key":"88005_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12885-023-10654-3","volume":"23","author":"S Kobayashi","year":"2023","unstructured":"Kobayashi, S. et al. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study. BMC Cancer. 23, 177 (2023).","journal-title":"BMC Cancer"},{"key":"88005_CR30","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.3390\/jcm12103477","volume":"12","author":"T Ikoma","year":"2023","unstructured":"Ikoma, T. et al. A retrospective study investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly patients with unresectable pancreatic Cancer. J. Clin. Med. 12, 3477 (2023).","journal-title":"J. Clin. Med."},{"key":"88005_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4240\/wjgs.v2.i1.14","volume":"2","author":"S Shimoyama","year":"2010","unstructured":"Shimoyama, S. Pharmacogenetics of irinotecan: an ethnicity-based prediction of irinotecan adverse events. World J. Gastrointest. Surg. 2, 14\u201321 (2010).","journal-title":"World J. Gastrointest. Surg."},{"key":"88005_CR32","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1111\/ajco.13028","volume":"14","author":"Y Yang","year":"2018","unstructured":"Yang, Y. et al. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: a meta-analysis. Asia Pac. J. Clin. Oncol. 14, e479\u2013e489 (2018).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"88005_CR33","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00520-010-0928-4","volume":"19","author":"S Ahn","year":"2011","unstructured":"Ahn, S. et al. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer. 19, 1151\u20131158 (2011).","journal-title":"Support Care Cancer"},{"key":"88005_CR34","doi-asserted-by":"publisher","first-page":"100746","DOI":"10.1016\/j.esmoop.2022.100746","volume":"8","author":"Y-Y Su","year":"2023","unstructured":"Su, Y-Y. et al. The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan. ESMO Open. 8, 100746 (2023).","journal-title":"ESMO Open."},{"key":"88005_CR35","doi-asserted-by":"crossref","unstructured":"Chiu, T. et al. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients\u2019 experience within a population-based study. Ther. Adv. Med. Oncol. 13 (2021).","DOI":"10.1177\/17588359211058255"},{"key":"88005_CR36","first-page":"5062","volume":"12","author":"N-J Chiang","year":"2022","unstructured":"Chiang, N-J. et al. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma. Am. J. Cancer Res. 12, 5062\u20135073 (2022).","journal-title":"Am. J. Cancer Res."},{"key":"88005_CR37","first-page":"null","volume":"12","author":"Y-Y Su","year":"2022","unstructured":"Su, Y-Y. et al. Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic Cancer: a real-world Multicenter Study. Front. Oncol. 12, null (2022).","journal-title":"Front. Oncol."},{"key":"88005_CR38","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402, 1272\u20131281 (2023).","journal-title":"Lancet"},{"key":"88005_CR39","doi-asserted-by":"publisher","first-page":"12422","DOI":"10.1038\/s41598-024-63172-y","volume":"14","author":"T Kodama","year":"2024","unstructured":"Kodama, T. et al. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer. Sci. Rep. 14, 12422 (2024).","journal-title":"Sci. Rep."},{"key":"88005_CR40","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"88005_CR41","unstructured":"Common Terminology. Criteria for Adverse Events (CTCAE) v5.0."},{"key":"88005_CR42","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1016\/S1470-2045(18)30098-6","volume":"19","author":"ET Veer","year":"2018","unstructured":"Veer, E. T. et al. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol. 19, e151\u2013e160 (2018).","journal-title":"Lancet Oncol."},{"key":"88005_CR43","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transpl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88005-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88005-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88005-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T19:45:52Z","timestamp":1738007152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88005-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["88005"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-88005-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"29 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AH reports honoraria from Taiho, Ono, Eisai, Chugai, Lilly, Daiichi Sankyo, Yakult, and Nippon Zoki. There are no competing interests or financial disclosures for the remaining authors to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Given that this study only utilized existing information and did not involve obtaining new samples or data, formal written or oral informed consent was not needed from the participants in compliance with the principles of the Declaration of Helsinki and the relevant Japanese laws regarding human subject research (Clinical Trials Act), the Institutional Review Boards of the participating institutions approved that formal written or verbal informed consent from participants was not required. However, the Law assures that patients or their proxies have the opportunity to decline participation in the investigation by refusing to be included if the research details were disclosed on the participating institutions\u2019 websites. The study protocol was approved by the central approval of the Institutional review board of Sasebo Kyosai Hospital (Study ID 2021-08), and also with the approval of the Institutional review boards or ethics committees of the following institutions: Nagasaki University Hospital, Kagoshima City Hospital, National Cancer Center Hospital East, Kagoshima University Hospital, Kurume University Hospital, Saga Medical Center Koseikan, Japanese Red Cross Kumamoto Hospital, Karatsu Red Cross Hospital, Japan Community Healthcare Organization Kyushu Hospital, Japanese Red Cross Nagasaki Genbaku Hospital, Oita University Hospital, University of Miyazaki Hospital, National Hospital Organization Kumamoto Medical Center, Saiseikai Kumamoto Hospital, Kagoshima Kouseiren Hospital, Miyazaki Prefectural Miyazaki Hospital, Izumi General Medical Center, Asakura Medical Association Hospital, and Saiseikai Sendai Hospital. All of the hospitals judged that the need for informed consent could be waived in compliance with the Japanese laws.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for consent for publication was obtained using the opt-in\/opt-out approach according to each participating institution\u2019s policy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"3427"}}